Home Casteddu.com	FAQ My Amedeo About	Flying Publisher
	The Medical Article of the Year 2008

Colorectal Neoplasms

Free Subscription Articles published in Ann Oncol Retrieve available abstracts of 63 articles: HTML format

Single Articles

June 2008
1. LURJE G , Zhang W, Schultheis AM, Yang D, et al
   Polymorphisms in VEGF and IL-8 predict tumor recurrence in stage III colon cancer.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
2. ROTHENBERG ML , Cox JV, Butts C, Navarro M, et al
   Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/folinic acid plus oxaliplatin (FOLFOX-4) as second-line therapy in metastatic colorectal cancer: a randomized phase III noninferiority study.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   May 2008
3. MEULENBELD HJ , van Steenbergen LN, Janssen-Heijnen ML, Lemmens VE, et al
   Significant improvement in survival of patients presenting with metastatic colon cancer in the south of The Netherlands from 1990 to 2004.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
4. VAN CUTSEM EJ , Oliveira J
   Advanced colorectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
   Ann Oncol. 2008;19 Suppl 2:ii33-4.
   PubMed     Related articles   
   
   
   
5. VAN CUTSEM EJ , Oliveira J
   Colon cancer: ESMO clinical recommendations for diagnosis, adjuvant treatment and follow-up.
   Ann Oncol. 2008;19 Suppl 2:ii29-30.
   PubMed     Related articles   
   
   
   
6. GLIMELIUS B , Oliveira J
   Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
   Ann Oncol. 2008;19 Suppl 2:ii31-2.
   PubMed     Related articles   
   
   
   April 2008
7. ARNOLD D , Hohler T, Dittrich C, Lordick F, et al
   Cetuximab in combination with weekly 5-fluorouracil/folinic acid and oxaliplatin (FUFOX) in untreated patients with advanced colorectal cancer: a phase Ib/II study of the AIO GI Group.
   Ann Oncol. 2008;.
   PubMed     Related articles    Abstract available
   
   
   
8. BOSETTI C , Bertuccio P, Levi F, Lucchini F, et al
   Cancer mortality in the European Union, 1970-2003, with a joinpoint analysis.
   Ann Oncol. 2008;19:631-40.
   PubMed     Related articles    Abstract available
   
   
   
9. RAPP K , Klenk J, Ulmer H, Concin H, et al
   Weight change and cancer risk in a cohort of more than 65,000 adults in Austria.
   Ann Oncol. 2008;19:641-8.
   PubMed     Related articles    Abstract available
   
   
   March 2008
10. BORNER M , Koeberle D, Von Moos R, Saletti P, et al
    Adding cetuximab to capecitabine plus oxaliplatin (XELOX) in first-line treatment of metastatic colorectal cancer: a randomized phase II trial of the Swiss Group for Clinical Cancer Research SAKK.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
11. 
    In this issue.
    Ann Oncol. 2008;19:405.
    PubMed     Related articles   
    
    
    
12. JEUNG HC , Moon YW, Rha SY, Yoo NC, et al
    Phase III trial of adjuvant 5-fluorouracil and adriamycin versus 5-fluorouracil, adriamycin, and polyadenylic-polyuridylic acid (poly A:U) for locally advanced gastric cancer after curative surgery: final results of 15-year follow-up.
    Ann Oncol. 2008;19:520-6.
    PubMed     Related articles    Abstract available
    
    
    
13. CHENG XJ , Xu W, Zhang QY, Zhou RL, et al
    Relationship between LAPTM4B gene polymorphism and susceptibility of colorectal and esophageal cancers.
    Ann Oncol. 2008;19:527-32.
    PubMed     Related articles    Abstract available
    
    
    February 2008
14. QVORTRUP C , Yilmaz M, Ogreid D, Berglund A, et al
    Chronomodulated capecitabine in combination with short-time oxaliplatin: a Nordic phase II study of second-line therapy in patients with metastatic colorectal cancer after failure to irinotecan and 5-flourouracil.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
15. PFEIFFER P , Nielsen D, Bjerregaard J, Qvortrup C, et al
    Biweekly cetuximab and irinotecan as third-line therapy in patients with advanced colorectal cancer after failure to irinotecan, oxaliplatin and 5-fluorouracil.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
16. TOL J , Koopman M, Rodenburg CJ, Cats A, et al
    A randomised phase III study on capecitabine, oxaliplatin and bevacizumab with or without cetuximab in first-line advanced colorectal cancer, the CAIRO2 study of the Dutch Colorectal Cancer Group (DCCG). An interim analysis of toxicity.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
17. SOONG R , Shah N, Salto-Tellez M, Tai BC, et al
    Prognostic significance of thymidylate synthase, dihydropyrimidine dehydrogenase and thymidine phosphorylase protein expression in colorectal cancer patients treated with or without 5-fluorouracil-based chemotherapy.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
18. BERGLUND A , Cedermark B, Glimelius B
    Is it deleterious to delay the start of adjuvant chemotherapy in colon cancer stage III?
    Ann Oncol. 2008;19:400-2.
    PubMed     Related articles   
    
    
    January 2008
19. SASTRE J , Maestro ML, Puente J, Veganzones S, et al
    Circulating tumor cells in colorectal cancer: correlation with clinical and pathological variables.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    
20. GLIMELIUS B , Sorbye H, Balteskard L, Bystrom P, et al
    A randomized phase III multicenter trial comparing irinotecan in combination with the Nordic bolus 5-FU and folinic acid schedule or the bolus/infused de Gramont schedule (Lv5FU2) in patients with metastatic colorectal cancer.
    Ann Oncol. 2008;.
    PubMed     Related articles    Abstract available
    
    
    December 2007
21. PESSINO A , Artale S, Sciallero S, Guglielmi A, et al
    First-line single-agent cetuximab in patients with advanced colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
22. KOHNE CH , De Greve J, Hartmann JT, Lang I, et al
    Irinotecan combined with infusional 5-fluorouracil/folinic acid or capecitabine plus celecoxib or placebo in the first-line treatment of patients with metastatic colorectal cancer. EORTC study 40015.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    November 2007
23. DE ROOCK W , Piessevaux H, De Schutter J, Janssens M, et al
    KRAS wild-type state predicts survival and is associated to early radiological response in metastatic colorectal cancer treated with cetuximab.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
24. VAN CUTSEM E , Verslype C, Beale P, Clarke S, et al
    A phase Ib dose-escalation study of erlotinib, capecitabine and oxaliplatin in metastatic colorectal cancer patients.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
25. ASCHELE C , Lonardi S
    Multidisciplinary treatment of rectal cancer: medical oncology.
    Ann Oncol. 2007;18:1908-15.
    PubMed     Related articles   
    
    
    
26. WEAVER A , Young AM, Rowntree J, Townsend N, et al
    Application of mobile phone technology for managing chemotherapy-associated side-effects.
    Ann Oncol. 2007;18:1887-92.
    PubMed     Related articles    Abstract available
    
    
    October 2007
27. CAPPUZZO F , Finocchiaro G, Rossi E, Janne PA, et al
    EGFR FISH assay predicts for response to cetuximab in chemotherapy refractory colorectal cancer patients.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
28. GALLAGHER DJ , Capanu M, Raggio G, Kemeny N, et al
    Hepatic arterial infusion plus systemic irinotecan in patients with unresectable hepatic metastases from colorectal cancer previously treated with systemic oxaliplatin: a retrospective analysis.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
29. DE GEUS-OEI LF , van Laarhoven HW, Visser EP, Hermsen R, et al
    Chemotherapy response evaluation with FDG PET in patients with colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    September 2007
30. BAJETTA E , Celio L, Ferrario E, Di Bartolomeo M, et al
    Capecitabine plus oxaliplatin and irinotecan regimen every other week: a phase I/II study in first-line treatment of metastatic colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
31. FORSTI A , Lei H, Tavelin B, Enquist K, et al
    Polymorphisms in the genes of the urokinase plasminogen activation system in relation to colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
32. BECOUARN Y , Senesse P, Thezenas S, Boucher E, et al
    A randomized phase II trial evaluating safety and efficacy of an experimental chemotherapy regimen (irinotecan + oxaliplatin, IRINOX) and two standard arms (LV5 FU2 + irinotecan or LV5 FU2 + oxaliplatin) in first-line metastatic colorectal cancer: a stud
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
33. VAN CUTSEM E , Siena S, Humblet Y, Canon JL, et al
    An open-label, single-arm study assessing safety and efficacy of panitumumab in patients with metastatic colorectal cancer refractory to standard chemotherapy.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
34. CORRAO G , Zambon A, Conti V, Nicotra F, et al
    Menopause hormone replacement therapy and cancer risk: an Italian record linkage investigation.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
35. RUTHOTTO F , Papendorf F, Wegener G, Unger G, et al
    Participation in screening colonoscopy in first-degree relatives from patients with colorectal cancer.
    Ann Oncol. 2007;18:1518-22.
    PubMed     Related articles    Abstract available
    
    
    July 2007
36. SORBYE H , Kohne CH, Sargent D, Glimelius B, et al
    Patient characteristics and stratification in medical treatment studies for metastatic colorectal cancer: A proposal for standardization of patient characteristic reporting and stratification.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
37. CERVANTES A , Rodriguez-Braun E, Navarro S, Hernandez A, et al
    Integrative decisions in rectal cancer.
    Ann Oncol. 2007;18 Suppl 9:ix127-31.
    PubMed     Related articles   
    
    
    
38. NAGTEGAAL ID , van Krieken JH
    The multidisciplinary treatment of rectal cancer: pathology.
    Ann Oncol. 2007;18 Suppl 9:ix122-6.
    PubMed     Related articles   
    
    
    
39. ASCHELE C , Lonardi S
    Multidisciplinary treatment of rectal cancer: medical oncology.
    Ann Oncol. 2007;18 Suppl 9:ix114-21.
    PubMed     Related articles   
    
    
    
40. DEUTSCH E , Ezra P, Mangoni M, Ducreux M, et al
    Radiotherapy for localized rectal cancer.
    Ann Oncol. 2007;18 Suppl 9:ix105-13.
    PubMed     Related articles   
    
    
    
41. FIGUERAS J , Burdio F, Ramos E, Torras J, et al
    Effect of subcentimeter nonpositive resection margin on hepatic recurrence in patients undergoing hepatectomy for colorectal liver metastases. Evidences from 663 liver resections.
    Ann Oncol. 2007;18:1190-5.
    PubMed     Related articles    Abstract available
    
    
    June 2007
42. MAIELLO E , Giuliani F, Gebbia V, Piano A, et al
    Cetuximab: clinical results in colorectal cancer.
    Ann Oncol. 2007;18 Suppl 6:vi8-10.
    PubMed     Related articles    Abstract available
    
    
    
43. KODA M , Sulkowska M, Kanczuga-Koda L, Cascio S, et al
    Expression of the obesity hormone leptin and its receptor correlates with hypoxia-inducible factor-1alpha in human colorectal cancer.
    Ann Oncol. 2007;18 Suppl 6:vi116-9.
    PubMed     Related articles    Abstract available
    
    
    
44. BARNI S , Venturini M, Beretta GD, Gori S, et al
    Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM).
    Ann Oncol. 2007;18 Suppl 6:vi179-84.
    PubMed     Related articles    Abstract available
    
    
    
45. CARTENI G , Fiorentino R, Vecchione L, Chiurazzi B, et al
    Panitumumab a novel drug in cancer treatment.
    Ann Oncol. 2007;18 Suppl 6:vi16-21.
    PubMed     Related articles    Abstract available
    
    
    May 2007
46. MEYERHARDT J , Stuart K, Fuchs C, Zhu A, et al
    Phase II study of FOLFOX, bevacizumab and erlotinib as first-line therapy for patients with metastastic colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
47. 
    Advanced colorectal cancer: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
    Ann Oncol. 2007;18 Suppl 2:ii25-ii26.
    PubMed     Related articles       Free Full Text
    
    
    
48. 
    Colon cancer: ESMO Clinical Recommendations for diagnosis, adjuvant treatment and follow-up.
    Ann Oncol. 2007;18 Suppl 2:ii21-ii22.
    PubMed     Related articles       Free Full Text
    
    
    
49. HELBLING D , Borner M
    Successful challenge with the fully human EGFR antibody panitumumab following an infusion reaction with the chimeric EGFR antibody cetuximab.
    Ann Oncol. 2007;18:963-4.
    PubMed     Related articles   
    
    
    April 2007
50. HERBERTSON R , Lee S, Tebbutt N, Scott A, et al
    The expanding role of PET technology in the management of patients with colorectal cancer.
    Ann Oncol. 2007;.
    PubMed     Related articles    Abstract available
    
    
    
51. MOK TS , Yeo W, Johnson PJ, Hui P, et al
    A double-blind placebo-controlled randomized study of Chinese herbal medicine as complementary therapy for reduction of chemotherapy-induced toxicity.
    Ann Oncol. 2007;18:768-74.
    PubMed     Related articles    Abstract available
    
    
    
52. MACHIELS JP , Sempoux C, Scalliet P, Coche JC, et al
    Phase I/II study of preoperative cetuximab, capecitabine, and external beam radiotherapy in patients with rectal cancer.
    Ann Oncol. 2007;18:738-44.
    PubMed     Related articles    Abstract available
    
    
    
53. GLIMELIUS B
    Rectal cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up.
    Ann Oncol. 2007;18 Suppl 2:ii23-4.
    PubMed     Related articles       Free Full Text
    
    
    March 2007
54. BOSCH TM , Meijerman I, Beijnen JH, van Thiel SW, et al
    Lethal toxicity of uracil/tegafur in the treatment of sigmoid carcinoma.
    Ann Oncol. 2007;18:607-8.
    PubMed     Related articles   
    
    
    February 2007
55. RUBBIA-BRANDT L , Giostra E, Brezault C, Roth AD, et al
    Importance of histological tumor response assessment in predicting the outcome in patients with colorectal liver metastases treated with neo-adjuvant chemotherapy followed by liver surgery.
    Ann Oncol. 2007;18:299-304.
    PubMed     Related articles    Abstract available
    
    
    September 2006
56. CERVANTES A , Chirivella I, Rodriguez-Braun E, Campos S, et al
    A multimodality approach to localized rectal cancer.
    Ann Oncol. 2006;17 Suppl 10:x129-34.
    PubMed     Related articles   
    
    
    February 2006
57. KOHNE CH , Folprecht G
    On prejudice and facts and choices.
    Ann Oncol. 2006;17:185-7.
    PubMed     Related articles       Free Full Text
    
    
    
58. TWELVES C , Gollins S, Grieve R, Samuel L, et al
    A randomised cross-over trial comparing patient preference for oral capecitabine and 5-fluorouracil/leucovorin regimens in patients with advanced colorectal cancer.
    Ann Oncol. 2006;17:239-45.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
59. MITA MM , Ochoa L, Rowinsky EK, Kuhn J, et al
    A phase I, pharmacokinetic and biologic correlative study of oblimersen sodium (Genasense, G3139) and irinotecan in patients with metastatic colorectal cancer.
    Ann Oncol. 2006;17:313-21.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
60. PFEIFFER P , Sorbye H, Ehrsson H, Fokstuen T, et al
    Short-time infusion of oxaliplatin in combination with capecitabine (XELOX30) as second-line therapy in patients with advanced colorectal cancer after failure to irinotecan and 5-fluorouracil.
    Ann Oncol. 2006;17:252-8.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
61. HOTTE SJ , Oza A, Winquist EW, Moore M, et al
    Phase I trial of UCN-01 in combination with topotecan in patients with advanced solid cancers: a Princess Margaret Hospital Phase II Consortium study.
    Ann Oncol. 2006;17:334-40.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
62. DE PAOLI A , Chiara S, Luppi G, Friso ML, et al
    Capecitabine in combination with preoperative radiation therapy in locally advanced, resectable, rectal cancer: a multicentric phase II study.
    Ann Oncol. 2006;17:246-51.
    PubMed     Related articles    Abstract available   Free Full Text
    
    
    
63. SIU SW , Chan RT, Au GK
    Hypersensitivity reactions to oxaliplatin: experience in a single institute.
    Ann Oncol. 2006;17:259-61.
    PubMed     Related articles    Abstract available   Free Full Text
    
    

Thank you for your interest in scientific medicine.

Amedeo is a Bernd Sebastian Kamps website.    Design: